CollPlant Stock Plummets 25% Amid Mixed Reaction to Dermal Filler Trial Results
CollPlant Biotechnologies saw its shares tumble 25% on Tuesday despite positive results from a non-clinical trial of its innovative photocurable dermal filler. The company's rhCollagen-based gel, designed to harden under light exposure for long-lasting aesthetic results, failed to impress investors despite management's enthusiasm.
CEO Yehiel Tal touted the technology's potential to redefine aesthetic medicine standards, emphasizing its dual capability for immediate contouring and natural tissue integration. The market's bearish response contrasts sharply with CollPlant's plans to scale production ahead of clinical trials that will determine the product's safety and efficacy.